FDA approves dasatinib for children with Philadelphia chromosome-positive chronic myeloid leukemia

The FDA expanded the indication for dasatinib to include the treatment of children with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

Read more: https://www.healio.com/hematology-oncology/pediatric-oncology/news/online/%7Bb3283d2f-98a0-49d1-8b61-498b87a58598%7D/fda-approves-dasatinib-for-children-with-philadelphia-chromosome-positive-chronic-myeloid-leukemia